Login / Signup

Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China.

Wei LiLi Wan
Published in: Expert review of pharmacoeconomics & outcomes research (2024)
ORIENT-16, www.clinicaltrials.gov, identifier is NCT03745170.
Keyphrases
  • locally advanced
  • papillary thyroid
  • squamous cell carcinoma
  • rectal cancer
  • radiation therapy
  • young adults